Research
Print page
Switch language
Rigshospitalet
- a part of Copenhagen University Hospital
Published
Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease
Research output: Contribution to journal › Journal article › Research › peer-review
Infliximab (IFX) is a chimeric murine/human anti-TNF antibody (Ab) used for the treatment of Crohn's disease (CD) and ulcerative colitis (UC). Loss of response is common and associated with development of anti-IFX Abs during ongoing therapy. However, human anti-murine immunoglobulin Abs are common and may cross-react with the murine part of IFX.
| Original language | English |
|---|---|
| Journal | Alimentary Pharmacology and Therapeutics |
| Volume | 37 |
| Issue number | 12 |
| Pages (from-to) | 1172-83 |
| Number of pages | 12 |
| ISSN | 0269-2813 |
| DOIs | |
| Publication status | Published - Jun 2013 |
ID: 39765484